NOX4 Inhibitor Platform
Stroke
Key Facts
About Glucox Biotech
Glucox Biotech is a preclinical-stage, private biotech firm pioneering the development of selective NOX4 inhibitors for metabolic and vascular diseases. The company's scientific foundation is built on targeting NADPH oxidase 4 (NOX4), an enzyme implicated in oxidative stress pathways driving diabetic complications, stroke, and kidney injury. Its lead candidate, GLX7013114, has been featured in peer-reviewed research for diabetic retinopathy, validating its approach. Glucox operates as a research-focused entity seeking academic and industry partnerships to advance its pipeline toward clinical development.
View full company profileAbout Glucox Biotech
Glucox Biotech is a preclinical-stage, private biotech firm pioneering the development of selective NOX4 inhibitors for metabolic and vascular diseases. The company's scientific foundation is built on targeting NADPH oxidase 4 (NOX4), an enzyme implicated in oxidative stress pathways driving diabetic complications, stroke, and kidney injury. Its lead candidate, GLX7013114, has been featured in peer-reviewed research for diabetic retinopathy, validating its approach. Glucox operates as a research-focused entity seeking academic and industry partnerships to advance its pipeline toward clinical development.
View full company profileTherapeutic Areas
Other Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| LG3 | Stream Biomedical | Pre-clinical |
| Patient Transport Optimization | Zeto | Research |
| NA-911 | Biomed | Phase 2A |
| DIASTROKE | Diagenics | Development/Commercial |
| APOSEC | Aposcience | Pre-clinical |
| NXL-001 | NeuExcell Therapeutics | Phase 1 |
| Precision Neuromodulation for Stroke Recovery | Panaxium | Pre-clinical |
| Autologous Wnt-activated ADSC Therapy | Regeneration Biomedical | Pre-clinical |
| NaviFUS Neuromodulation for Stroke Rehabilitation | NaviFUS | Phase 1 |
| Banked Cord Blood Stem Cells | Cryo-Cell | Clinical Trials |